Cargando…
First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID‐19 in an allogeneic stem cell transplant patient
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175733/ https://www.ncbi.nlm.nih.gov/pubmed/35846103 http://dx.doi.org/10.1002/jha2.132 |
| _version_ | 1784722513384701952 |
|---|---|
| author | Fordham, Nicholas Baker, Emma Forton, Daniel Klammer, Matthias Patel, Kamal Qadir, Dara Reyal, Yasmin Willis, Fenella Koh, Mickey B.C. |
| author_facet | Fordham, Nicholas Baker, Emma Forton, Daniel Klammer, Matthias Patel, Kamal Qadir, Dara Reyal, Yasmin Willis, Fenella Koh, Mickey B.C. |
| author_sort | Fordham, Nicholas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9175733 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91757332022-07-14 First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID‐19 in an allogeneic stem cell transplant patient Fordham, Nicholas Baker, Emma Forton, Daniel Klammer, Matthias Patel, Kamal Qadir, Dara Reyal, Yasmin Willis, Fenella Koh, Mickey B.C. EJHaem Case Reports John Wiley and Sons Inc. 2020-12-08 /pmc/articles/PMC9175733/ /pubmed/35846103 http://dx.doi.org/10.1002/jha2.132 Text en © 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Case Reports Fordham, Nicholas Baker, Emma Forton, Daniel Klammer, Matthias Patel, Kamal Qadir, Dara Reyal, Yasmin Willis, Fenella Koh, Mickey B.C. First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID‐19 in an allogeneic stem cell transplant patient |
| title | First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID‐19 in an allogeneic stem cell transplant patient |
| title_full | First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID‐19 in an allogeneic stem cell transplant patient |
| title_fullStr | First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID‐19 in an allogeneic stem cell transplant patient |
| title_full_unstemmed | First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID‐19 in an allogeneic stem cell transplant patient |
| title_short | First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID‐19 in an allogeneic stem cell transplant patient |
| title_sort | first reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with covid‐19 in an allogeneic stem cell transplant patient |
| topic | Case Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175733/ https://www.ncbi.nlm.nih.gov/pubmed/35846103 http://dx.doi.org/10.1002/jha2.132 |
| work_keys_str_mv | AT fordhamnicholas firstreportedcaseofsafeandefficacioususeoftocilizumabfortreatmentofhyperinflammatorysyndromeassociatedwithcovid19inanallogeneicstemcelltransplantpatient AT bakeremma firstreportedcaseofsafeandefficacioususeoftocilizumabfortreatmentofhyperinflammatorysyndromeassociatedwithcovid19inanallogeneicstemcelltransplantpatient AT fortondaniel firstreportedcaseofsafeandefficacioususeoftocilizumabfortreatmentofhyperinflammatorysyndromeassociatedwithcovid19inanallogeneicstemcelltransplantpatient AT klammermatthias firstreportedcaseofsafeandefficacioususeoftocilizumabfortreatmentofhyperinflammatorysyndromeassociatedwithcovid19inanallogeneicstemcelltransplantpatient AT patelkamal firstreportedcaseofsafeandefficacioususeoftocilizumabfortreatmentofhyperinflammatorysyndromeassociatedwithcovid19inanallogeneicstemcelltransplantpatient AT qadirdara firstreportedcaseofsafeandefficacioususeoftocilizumabfortreatmentofhyperinflammatorysyndromeassociatedwithcovid19inanallogeneicstemcelltransplantpatient AT reyalyasmin firstreportedcaseofsafeandefficacioususeoftocilizumabfortreatmentofhyperinflammatorysyndromeassociatedwithcovid19inanallogeneicstemcelltransplantpatient AT willisfenella firstreportedcaseofsafeandefficacioususeoftocilizumabfortreatmentofhyperinflammatorysyndromeassociatedwithcovid19inanallogeneicstemcelltransplantpatient AT kohmickeybc firstreportedcaseofsafeandefficacioususeoftocilizumabfortreatmentofhyperinflammatorysyndromeassociatedwithcovid19inanallogeneicstemcelltransplantpatient |